On Tuesday, Tarsus Pharmaceuticals Inc (NASDAQ: TARS) was -4.77% drop from the session before settling in for the closing price of $51.37. A 52-week range for TARS has been $20.08 – $57.28.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 172.29%. When this article was written, the company’s average yearly earnings per share was at 46.82%. With a float of $35.81 million, this company’s outstanding shares have now reached $38.35 million.
Let’s determine the extent of company efficiency that accounts for 323 employees. In terms of profitability, gross margin is 92.99%, operating margin of -65.9%, and the pretax margin is -63.16%.
Tarsus Pharmaceuticals Inc (TARS) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Tarsus Pharmaceuticals Inc stocks. The insider ownership of Tarsus Pharmaceuticals Inc is 13.92%, while institutional ownership is 94.60%. The most recent insider transaction that took place on Mar 24 ’25, was worth 300,000. In this transaction President/CEO and Board Chair of this company sold 6,000 shares at a rate of $50.00, taking the stock ownership to the 824,106 shares. Before that another transaction happened on Mar 24 ’25, when Company’s Officer proposed sale 6,000 for $50.00, making the entire transaction worth $300,000.
Tarsus Pharmaceuticals Inc (TARS) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 46.82% per share during the next fiscal year.
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) Trading Performance Indicators
You can see what Tarsus Pharmaceuticals Inc (TARS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.39. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.13.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.10, a number that is poised to hit -0.77 in the next quarter and is forecasted to reach 1.24 in one year’s time.
Technical Analysis of Tarsus Pharmaceuticals Inc (TARS)
Looking closely at Tarsus Pharmaceuticals Inc (NASDAQ: TARS), its last 5-days average volume was 0.76 million, which is a jump from its year-to-date volume of 0.67 million. As of the previous 9 days, the stock’s Stochastic %D was 63.94%. Additionally, its Average True Range was 2.72.
During the past 100 days, Tarsus Pharmaceuticals Inc’s (TARS) raw stochastic average was set at 50.44%, which indicates a significant increase from 49.93% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 47.99% in the past 14 days, which was lower than the 50.66% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $49.07, while its 200-day Moving Average is $40.12. However, in the short run, Tarsus Pharmaceuticals Inc’s stock first resistance to watch stands at $50.60. Second resistance stands at $52.28. The third major resistance level sits at $53.23. If the price goes on to break the first support level at $47.97, it is likely to go to the next support level at $47.02. Should the price break the second support level, the third support level stands at $45.34.
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) Key Stats
There are 38,377K outstanding shares of the company, which has a market capitalization of 2.04 billion. As of now, sales total 182,950 K while income totals -115,550 K. Its latest quarter income was 66,410 K while its last quarter net income were -23,110 K.
